. This has been partly because of inadequate patient numbers in many of the trials, but also to do with problems of compliance in the case of hyperbaric oxygen and unacceptable toxcity in the case of sensitisers (Henk, 1981; Dische, 1985) . Current approaches should now address the issue of tumour repopulation (Dische, 1991) as well as the existence in tumours of both acute and chronic hypoxia (Coleman, 1988) .
Combining nicotinamide with carbogen breathing (95% oxygen, 5% carbon dioxide) and accelerated hyperfractionated radiation regimens (ARCON) is one such approach currently being evaluated in Europe. Both nicotinanude and carbogen breathilg (aimed at overcoming acute and chronic hypoxia respectively) can enhance radiosensitivity and improve the therapeutic ratio in murine tumours when used alone (Horsman et al., 1987; Horsman et al., 1989; Rojas, 1991) . Maximum enhancement is achieved when the agents are used in combination and has been demonstrated with both single and multifraction radiation treatments (Kiellen et al., 1991; Chaplin et al., 1993; Simon et al., 1993) . By delivering the radiation in an accelerated regimen, in an attempt to prevent tumour repopulation, even further enhancement can be achieved (Rojas, 1992) . Clinical studies using combinations of these agents are now under way in patients, but their exact modes of action and optimum ways of delivery remain under investigation.
The B vitamin derivative nicotnamide appears to improve radiosensitivity primarily by overcoming acute hypoxia which may occur as a result of the transient closure of oxygen and nutrent supplying vessels within the tumour microcirulation (Horsman et al., 1988 , 1989 Chaplin et al., 1990) . Although it has been previously used with little toxicity in daily doses of up to 12 g in the treatment of benign disease (Zackheim, 1981) , its use in patients with neoplastic disease is novel. Its pharmacokinetics has been measured in man at doses up to 6 g (Stratford et al., 1992; Horsman et al., 1993a) , but its optimum dose, formulation and timing of administration in relation to radiation treatment are not yet fully established. Early studies suggested that radiosensitisation in murine tumour models occurs only at doses which would-be toxic in man (Brown, 1992) , but a recent study has suggested that enhancement is independent of dose provided that radiation is given when nicotinamide plasma concentration is at its peak (Horsman et al., 1993a) and that doses of 6 g in man should be enough to produce tumour sensitisation.
Normobaric oxygen and carbogen breathing are well established in animal models as radiation sensitsers (Rojas, 1991) . They are thought to overcome hypoxia by increasng the dissolved oxygen partial pressure (p02) and increasing the intracapllary haemoglobin saturation, thus maing more oxygen available to chronically depnved hypoxc tumour cells located beyond the maximum diffusion distance of oxygen (Kruuv et al., 1967) . The preirradiation breathing tim (PIBT) appears to be a critical factor in radiosensitisation, with optimum enhancement occurring within short defid time periods in murine tumours (Siemann et al., 1977) . However, its importance is diminished by the concurrent use of nicotinamide (Chaplin et al., 1993) . Some of the previous studies of carbogen and oxygen breathing in man may have failed owing to the use of extended periods of PIBT (Keresteci and Rider, 1973; Rubin et al., 1979) . However, in one randomised controlled study in patients with carcinoma of the cervix breathing normobaric oxygen for 5-10 min before inradiation, both local recurrence and overall survival were improved by the addition of oxygen (Bergsjo and Kolstad, 1968 (Kaflinowski et al., 1990; Vaupel et al., 1991 with BAT 10 data display system and was programmed into the histograph so that all p2 readings were corrected for temperature. The microelectrode probe was then inserted into the tumour through the cannula in order to protect the membrane of the cathode. The eectrode was allowed to stabiise and the set of measurements then taken. (Moroney, 1990) . Pharmacokinetic data were analysed using Kaleidagraph software (Albeck) for the calculations of means, standard errors and correlation coefficients.
Reasd
Nicotinmide ph/nnacokinetics Pharmacokinetic data were analysed from 12 patients and are shown in Table II ; four patients received a dose of 4 g, three received 5 g and five received 6 g. There was wide variation between patients in both peak plasma cotinamide concentration and time to reach it. The mean peak plasma nicotinamide concentrations were 82, 115 and 150pgml-' for doses of 4, 5 and 6g respectively, the overall mean ± l(s.e.) being 115 (± 10)pigml-'. There was a linear relationship between peak plasma nicotinamide concentration and nicotinamide dose expressed either in g, mg kg-' or g m-2 (correlation coefficients, R = 0.73, 0.68 and 0.73 respectively). Figure 1 shows the relationship between administered nicotinamide dose in grams and peak plasma nicotinamide concentration. In contrast, no relationship was found between dmid nicotinamide dose and the time of peak plasma nicotinamide concentration, which had an inter-patient range of 0.7-4 h with a mean ( s.e.) of 2.4 (± 0.3) h.
We were particularly concerned to begin carbogen breathing as near to the time of peak plasma nicotinamide concentration as possible. Having found marked variation in this time in the initial patients we then used the spectrophotometric assay in six subsequent patients. We assumed that peak nicotinamide concentration had been reached when a plateau or fall in UV absorption was detected. At this stage a set of oxygen measurements was performed and then carbogen breathing commenced. A time lag between the true time of the peak and commencement of carbogen thus inevitably occurred. Figure 2 shows the comparative profiles of the perctages of peak plasma nicotinamide concentrations in the Six patients as measured by the two different assays and their relationship to the time of carbogen breathing. It demonstrates that the rapid spectrophotometric assay gave a reasonable indication of the peak in all except one patient (no. 9). Of the five patients who breathed carbogen four (80%) had mean nicotinamide plasma concentrations (as measured by subsequent HPLC analysis) during gas breathing which were within 10% of the peak. In contrast, if a standard 90 min time to reach the peak had been assumed throughout the study, only 33% of the patients would have had nicotinamide plasma concentrations within 10% of the peak at the commencement of carbogen breathing (data not shown). Overall, the mean plasma concentration of nicotinamide during carbogen breathing was within 20% of peak plasma nicotinamide concentration in eight out of ten patients.
Toxicity associated with nicotinamide After nicotinamide administration 9 out of 12 patients suffered from some toxicity (Table I) . Diastolic blood pressure fell in three patients (> 15 mmHg diastolic), of whom two were asymptomatic and one had accompanying mild diziness. Five patients noticed flushing, one accompaied by mild nausea, and three had mild headaches. One patient with a long-standing history of asymptomatic hypertension, concurrently receiving bendrofluazide medication, suffered signifcant toxicity at the time of peak nicotinamide concentration, with profound hypotension resulting in a transient cardiorespiratory arrest. He quickly regained consciousness but ained relatively bradycardic and hypotensive for several hours. He recovered completdy with no further sequelae. (Hall, 1987) . Fige 3 Median P02 values and 10-90% inter-percentile ranges in ten patients before ingestion of nicotinamide (pre). at presumed peak plasma nicotinamide concentration (post-NCI) and at times 0-5, 5-10, 10-15 and > 15 min after commencement of carbogen breathing.
to rise significantly or remain in plateau in all except two (nos. 10 and 12). Of the six patients with pretreatment values of less than 5 mmHg, these had been completely abolished in three and were reduced in two during carbogen breathing. Patient no. 5 was the only patient who had previously been irradiated in the measured site and was also the only patient to show no significant rise in tumour median P02-
Dimscio
The aim of this study was to investigate whether combining treatment with nicotinamide and carbogen breathing altered P02 distribution in accessible tumours of patients with advanced malignant disease. In addition, data were obtained on changes in P02 after nicotinamide alone, nicotinamide pharmacokinetics and toxicity of the combined treatment.
The nicotinamide pharmacokinetic data confirmed and extended those for man already in the literature. Following doses of 4-6g in tablet formation (51-108mgkg-') the magnitude of peak concentration and plasma clearance were consistent with previous findings on normal volunteers (Stratford et al., 1992; Horsman et al., 1993a) and were both dose dependent. The time to reach peak plasma concentration was widely variable and was independent of dose, as in Stratford's study using the same formulation, but unlike Horsman's results using a capsule formulation, after which the time to reach peak concentration occurred predictably within 45 min of ingestion. There is clear evidence in an animal system that maximum radiosensitisation by nicotinamide occurs at the time of peak plasma concentration and surprisingly appears to be independent of the magnitude of the peak (Horsman et al., 1993a) . The efforts made in this study to deliver carbogen at the time of peak nicotinamide concentration were largely successful. The spectrophotometric assay was cumbersome but allowed reasonable assessment of the time of the peak. Nonetheless, a capsule or rapid release formulation with a more predictable time of peak concentration would clearly be an advantage. There has been some debate about the required dose of nicotinamide in humans which might achieve significant radiosensitisation without toxicity (Brown, 1992) . Initial studies suggested that optimum sensitisation could only be achieved in murine tumours with intraperitoneal (i.p.) doses of over 500 mg kg-l which were thought to translate into a dose in man which would be unacceptable in terms of toxicity (Horsman et al., 1987) . In a recent study of the comparative pharmacokinetics of nicotinamide in mouse and man, oral doses of 6 g in man gave rise to similar peak plasma levels as 171 mg kg-' i.p. nicotinamide in mice (Horsman et al., 1993a) , a dose which produced maximal enhancement of radiation damage in the mouse tumours provided that the radiation was delivered at the time of peak drug level. Thus assuming that a similar mechanism occurs in man, a 6 g dose should be adequate -to ensure enhancement of radiosensitisation provided that the radiation can be given at the time of peak plasma drug levels. This is a substantially smaller dose than was originally thought to be required.
Although 6 g is thought to be a safe dose in man, there still remain questions about potential toxicity. Neither study of nicotinamide pharmacokinetics in man reported major toxicity in healthy volunteers, although single instances of migraine and nausea and vomiting were reported (Stratford D0 et al., 1992; Horsman et al., 1993a) . Nicotinamide has been e ecxtensively and safely used in repeat dosage of up to 6 g in the treatment of a number of benign conditions (Zackheim, 1981) , but in the current study of patients with malignant disease most complained of minor side-effects. The hypoten-E sive episode occuring at peak plasma nicotinamide concent-E ration in one patient in the study is a cause for greater 0 concern. It is likely that this event was related to his concurrent diagnosis of hypertension and antihypertensive medication, but caution still needs to be maintained until further experience is gained of this drug in patients with malignant 0s disease. (Lee and Song, 1992) . In another study using 0_ a different tumour model, significant increases in hypoxic values ( <10 mmHg) were found despite an improvement in tumour blood flow (Kelleher and Vaupel, 1993 Between tracks in a patient 5625 18 313 F = Snedecor's variance ratio. P-value obtained from F-distrubiton tables, using the tabulated degrees of freedom. et al., 1994) . These observations are consistent with the findings of maximum enhancement of radiosensitisation occurring after combining the agents (Kjellen et al., 1991) .
In man there have been no other published studies of the measurement of tumour P02 distribution following combined treatment with nicotinamide and carbogen breathing. The findings of greater between-than within-tumour heterogeneity at three time points support the impression of wide individual variation between tumours and make pooling of individual patient data irrelevant. Each individual was therefore assessed separately, and nine out of ten showed significant rises in tumour oxygen distribution. As in our previous study of carbogen breathing alone (Falk et al., 1992) , we found a wide range of change in median p02 with elimination of some but not all values of p02 below 5 mmHg. The rises in median pO2 tended to be of greater magnitude than in the previous study and were sustained until 15 min and over in the majority of our patients, whereas in the previous study a fall in median tumour pO2 occurred in all patients between 12 and 18min. Our current results suggest that the combination of nicotinamide and carbogen breathing may give rise to greater improvements in tumour hypoxia than carbogen breathing alone, and in particular may result in a sustained rise rather than a rise followed by a progressive fall. These results are supported by experimental animal data. Thus Chaplin et al. (1993) have shown that the influence of the length of the preirradiation breathing time of carbogen on radiosensitivity was diminished by the concurrent use of nicotinamide, following which hypoxia was apparently abolished. Our findings, overall, support the results in experimental tumour models of a greater reduction in tumour hypoxia after the use of the combined agents compared with either agent alone. In addition, the combination appears to be effective over a longer time period than carbogen alone, which in the clinic would ensure less risk of missing the time of presumed tumour radiosensitisation.
In conclusion, we have treated ten patients with advanced malignant disease with the combination of oral nicotinamide and carbogen breathing before palliative radiotherapy and a further two patients received nicotinamide alone. Side-effects were generally mild except for one patient who suffered from a major toxic event. Despite being unable to demonstrate marked changes in tumour oxygen distribution close to peak plasma nicotinamide concentration and therefore at assumed optimum time for radiosensitisation, large and highly significant rises in median tumour P02 were demonstrated during carbogen breathing which were sustained for at least 15 min. Although these changes in P02 cannot be shown to be occurring in the milieu of the radioresistant hypoxic cells, our results are encouraging and should stimulate further clinical studies of this potentially highly effective combination of agents in order to establish whether the impressive therapeutic gains seen in animal models will be repeatable in man.
